Danish firm ALK secures global rights to neffy®, an adrenaline nasal spray for allergies, for $145M.

Danish pharmaceutical company ALK has secured exclusive global rights to neffy®, the first adrenaline nasal spray for emergency allergic reactions, excluding the USA, Australia, New Zealand, Japan, and China. The $145 million deal supports ALK's financial goals and diversifies its revenue. Neffy®, approved in the EU and US, offers a needle-free emergency treatment option for anaphylaxis, enhancing quick response capabilities.

November 09, 2024
7 Articles